Stay updated on BIO89-100 Multiple Dose in NASH Clinical Trial
Sign up to get notified when there's something new on the BIO89-100 Multiple Dose in NASH Clinical Trial page.

Latest updates to the BIO89-100 Multiple Dose in NASH Clinical Trial page
- Check6 days agoChange DetectedThe completed pegozafermin study record is displayed instead of the error page, with details on its design, outcomes, locations, eligibility criteria, and study documents.SummaryDifference73%

- Check13 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA general NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The clinical trial record remains inaccessible behind a 403 error.SummaryDifference1%

- Check41 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, shown with a basic HTML structure and site footer, indicating restricted access to the study information.SummaryDifference20%

- Check62 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0, indicating a software version upgrade. It represents a backend update reflected in the page's revision label.SummaryDifference0.0%

Stay in the know with updates to BIO89-100 Multiple Dose in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BIO89-100 Multiple Dose in NASH Clinical Trial page.